have recently corroborated in CCR7 engineered CD19 CAR t-haNK cells an improved migration toward LN chemokine CCL19 compared to only CD19-CAR t-haNK cells in an in vivo xenografted NSG lymphoma model (335). The gene discussed is CD19; the disease is lymphoma.